FDA Clears AI Software for Enhanced Lung Nodule Detection on Chest X-Rays
Tailored for incidental findings on chest radiographs, the qXR for Lung Nodule (qXR-LN) software utilizes artificial intelligence (AI) to help detect suspected pulmonary nodules ranging between 6 to 30 mm.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the artificial intelligence (AI)-enabled qXR for Lung Nodule (qXR-LN) software, which may enhance detection of pulmonary nodules on chest X-rays.
Qure.ai, the developer of the software, said qXR-LN detects and highlights regions of suspected pulmonary nodules, ranging between 6 to 30 mm in size. Geared to diagnosing incidental findings on chest radiographs, the AI software can also be utilized as a second reader in the review of AP and PA chest radiographs, according to Qure.ai.
The company noted that one multicenter study, involving 40 sites, revealed a 94 percent AUC for qXR-LN in stand-alone detection of lung nodule detection.
“Solutions like Qure.ai's qXR-LN are a significant step towards establishing new possibilities in pulmonary imaging, particularly within oncology. The need for early-stage lung cancer detection is crucial, and tools like qXR-LN can play a significant role in the early detection of incidental nodules,” noted Vishisht Mehta, M.D., F.C.C.P., the Director of Interventional Pulmonology at the Lung Center of Nevada in Las Vegas.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
Meta-Analysis Shows Merits of AI with CTA Detection of Coronary Artery Stenosis and Calcified Plaque
April 16th 2025Artificial intelligence demonstrated higher AUC, sensitivity, and specificity than radiologists for detecting coronary artery stenosis > 50 percent on computed tomography angiography (CTA), according to a new 17-study meta-analysis.
New bpMRI Study Suggests AI Offers Comparable Results to Radiologists for PCa Detection
April 15th 2025Demonstrating no significant difference with radiologist detection of clinically significant prostate cancer (csPCa), a biparametric MRI-based AI model provided an 88.4 percent sensitivity rate in a recent study.
